{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T21:18:26Z","timestamp":1790889506918,"version":"4.1.0"},"reference-count":63,"publisher":"BMJ","issue":"8","license":[{"start":{"date-parts":[[2020,8,17]],"date-time":"2020-08-17T00:00:00Z","timestamp":1597622400000},"content-version":"unspecified","delay-in-days":16,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100016302","name":"Coalition for Epidemic Preparedness Innovations","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100016302","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Glob Health"],"accepted":{"date-parts":[[2020,6,24]]},"published-print":{"date-parts":[[2020,8]]},"abstract":"<jats:p>Rift valley fever virus (RVFV) is a causative agent of a viral zoonosis that constitutes a major clinical burden in wild and domestic ruminants. The virus causes major outbreaks in livestock (sheep, goats, cattle and camels) and can be transmitted to humans by contaminated animal products or via arthropod vectors. Human-to-human transmission has not been reported to date, but spill-over events from animals have led to outbreaks in humans in Africa and the Arabian Peninsula. Currently, there is no licensed human vaccine against RVFV and the virus is listed as a priority pathogen by the World Health Organisation (WHO) due to the high epidemic potential and the lack of effective countermeasures. Multiple large RVFV outbreaks have been reported since the virus was discovered. During the last two decades, over 4000 cases and ~1000 deaths have been reported. The lack of systematic surveillance to estimate the true burden and incidence of human RVF disease is a challenge for planning future vaccine efficacy evaluation. This creates a need for robust diagnostic methodologies that can be deployed in remote regions to aid case confirmation, assessment of seroprevalence as well as pathogen surveillance required for the different stages of vaccine evaluation. Here, we perform comprehensive landscaping of the available diagnostic solutions for detection of RVFV in humans. Based on the identified gaps in the currently available in-house and commercially available methods, we highlight the specific investment needs for diagnostics that are critical for accelerating the development of effective vaccines against RVFV.<\/jats:p>","DOI":"10.1136\/bmjgh-2020-002694","type":"journal-article","created":{"date-parts":[[2020,8,18]],"date-time":"2020-08-18T05:12:11Z","timestamp":1597727531000},"page":"e002694","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":57,"title":["Rift valley fever: diagnostic challenges and investment needs for vaccine development"],"prefix":"10.1136","volume":"5","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5997-0173","authenticated-orcid":false,"given":"Velislava","family":"Petrova","sequence":"first","affiliation":[{"name":"Human Genetics Programme, Wellcome Sanger Institute, Cambridge, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Kristiansen","sequence":"additional","affiliation":[{"name":"Vaccine Research and Development, Coalition for Epidemic Preparedness Innovations, Oslo, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gunnstein","family":"Norheim","sequence":"additional","affiliation":[{"name":"Infectious Diseases, Vaccibody AS, Oslo, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Solomon A","family":"Yimer","sequence":"additional","affiliation":[{"name":"Vaccine Research and Development, Coalition for Epidemic Preparedness Innovations, Oslo, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2020,8,17]]},"reference":[{"key":"2025072915231370000_5.8.e002694.1","doi-asserted-by":"crossref","DOI":"10.1186\/s12941-020-0346-5","article-title":"The challenging management of Rift Valley fever in humans: literature review of the clinical disease and algorithm proposal","volume":"19","author":"Javelle","year":"2020","journal-title":"Ann Clin Microbiol Antimicrob"},{"key":"2025072915231370000_5.8.e002694.2","unstructured":"Daubney RH , Garnham PC . Enzootic hepatitis or Rift Valley fever. An undescribed virus disease of sheep cattle and man from Aast Africa. The journal of Pathology and Bacteriology."},{"key":"2025072915231370000_5.8.e002694.3","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1099\/jgv.0.001296","article-title":"Rift Valley fever: biology and epidemiology","volume":"100","author":"Wright","year":"2019","journal-title":"J Gen Virol"},{"key":"2025072915231370000_5.8.e002694.4","doi-asserted-by":"publisher","DOI":"10.1086\/378747"},{"key":"2025072915231370000_5.8.e002694.5","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1607948114"},{"key":"2025072915231370000_5.8.e002694.6","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0006576","article-title":"A comparative genome analysis of Rift Valley fever virus isolates from foci of the disease outbreak in South Africa in 2008-2010","volume":"13","author":"Maluleke","year":"2019","journal-title":"PLoS Negl Trop Dis"},{"key":"2025072915231370000_5.8.e002694.7","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1111\/tbed.12608","article-title":"Quantifying the potential pathways and locations of Rift Valley fever virus entry into the United States","volume":"65","author":"Golnar","year":"2018","journal-title":"Transbound Emerg Dis"},{"key":"2025072915231370000_5.8.e002694.8","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0003163"},{"key":"2025072915231370000_5.8.e002694.9","doi-asserted-by":"publisher","DOI":"10.2174\/1874357901004020008"},{"key":"2025072915231370000_5.8.e002694.10","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.73.10.8196-8200.1999"},{"key":"2025072915231370000_5.8.e002694.11","doi-asserted-by":"publisher","DOI":"10.1016\/0035-9203(79)90006-3"},{"key":"2025072915231370000_5.8.e002694.12","doi-asserted-by":"publisher","DOI":"10.4269\/ajtmh.2010.09-0318"},{"key":"2025072915231370000_5.8.e002694.13","doi-asserted-by":"publisher","DOI":"10.4269\/ajtmh.2010.09-0288"},{"key":"2025072915231370000_5.8.e002694.14","doi-asserted-by":"crossref","first-page":"e864","DOI":"10.1016\/S2214-109X(16)30176-0","article-title":"Association of Rift Valley fever virus infection with miscarriage in Sudanese women: a cross-sectional study","volume":"4","author":"Baudin","year":"2016","journal-title":"Lancet Glob Health"},{"key":"2025072915231370000_5.8.e002694.15","unstructured":"CDC . Rift Valley fever. Available: https:\/\/wwwnc.cdc.gov\/travel\/diseases\/rift-river-valley"},{"key":"2025072915231370000_5.8.e002694.16","first-page":"1047","article-title":"Acute renal failure associated with the Rift Valley fever: a single center study","volume":"20","author":"El Imam","year":"2009","journal-title":"Saudi J Kidney Dis Transpl"},{"key":"2025072915231370000_5.8.e002694.17","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2004.09.018"},{"key":"2025072915231370000_5.8.e002694.18","doi-asserted-by":"crossref","first-page":"29","DOI":"10.2807\/esm.09.12.00504-en","article-title":"Bichat guidelines for the clinical management of haemorrhagic fever viruses and bioterrorism-related haemorrhagic fever viruses","volume":"9","author":"Bossi","year":"2004","journal-title":"Euro Surveill"},{"key":"2025072915231370000_5.8.e002694.19","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-018-20362-9","article-title":"Anti-Rift Valley fever virus activity in vitro, pre-clinical pharmacokinetics and oral bioavailability of benzavir-2, a broad-acting antiviral compound","volume":"8","author":"Islam","year":"2018","journal-title":"Sci Rep"},{"key":"2025072915231370000_5.8.e002694.20","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2014.01.016"},{"key":"2025072915231370000_5.8.e002694.21","doi-asserted-by":"crossref","first-page":"3750","DOI":"10.1016\/j.celrep.2018.12.001","article-title":"A protective monoclonal antibody targets a site of vulnerability on the surface of Rift Valley fever virus","volume":"25","author":"Allen","year":"2018","journal-title":"Cell Rep"},{"key":"2025072915231370000_5.8.e002694.22","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0004314","article-title":"The risk of nosocomial transmission of Rift Valley fever","volume":"9","author":"Al-Hamdan","year":"2015","journal-title":"PLoS Negl Trop Dis"},{"key":"2025072915231370000_5.8.e002694.23","unstructured":"WHO . Introduction to Rift Valley fever. managing infectious hazards."},{"key":"2025072915231370000_5.8.e002694.24","doi-asserted-by":"publisher","DOI":"10.1016\/j.jviromet.2011.11.025"},{"key":"2025072915231370000_5.8.e002694.25","doi-asserted-by":"crossref","DOI":"10.2807\/1560-7917.ES.2019.24.8.1800213","article-title":"Tracking Rift Valley fever: from Mali to Europe and other countries, 2016","volume":"24","author":"Tong","year":"2019","journal-title":"Euro Surveill"},{"key":"2025072915231370000_5.8.e002694.26","doi-asserted-by":"publisher","DOI":"10.1186\/s12985-015-0392-3"},{"key":"2025072915231370000_5.8.e002694.27","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.01905-08"},{"key":"2025072915231370000_5.8.e002694.28","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0142129"},{"key":"2025072915231370000_5.8.e002694.29","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0002244"},{"key":"2025072915231370000_5.8.e002694.30","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.02095-06"},{"key":"2025072915231370000_5.8.e002694.31","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.40.7.2323-2330.2002"},{"key":"2025072915231370000_5.8.e002694.32","first-page":"49","article-title":"Indirect enzyme-linked immunosorbent assay for the detection of antibody against Rift Valley fever virus in domestic and wild ruminant sera","volume":"70","author":"Paweska","year":"2003","journal-title":"Onderstepoort J Vet Res"},{"key":"2025072915231370000_5.8.e002694.33","doi-asserted-by":"publisher","DOI":"10.1016\/j.jviromet.2008.12.003"},{"key":"2025072915231370000_5.8.e002694.34","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.jviromet.2012.09.016","article-title":"European ring trial to evaluate ELISAs for the diagnosis of infection with Rift Valley fever virus","volume":"187","author":"Kortekaas","year":"2013","journal-title":"J Virol Methods"},{"key":"2025072915231370000_5.8.e002694.35","doi-asserted-by":"publisher","DOI":"10.1186\/1743-422X-6-125"},{"key":"2025072915231370000_5.8.e002694.36","doi-asserted-by":"publisher","DOI":"10.1016\/j.jviromet.2007.07.017"},{"key":"2025072915231370000_5.8.e002694.37","doi-asserted-by":"publisher","DOI":"10.1016\/j.jviromet.2012.03.008"},{"key":"2025072915231370000_5.8.e002694.38","doi-asserted-by":"publisher","DOI":"10.1016\/j.virusres.2013.12.037"},{"key":"2025072915231370000_5.8.e002694.39","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.01412-08"},{"key":"2025072915231370000_5.8.e002694.40","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcv.2012.05.006"},{"key":"2025072915231370000_5.8.e002694.41","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1007\/s12010-017-2592-3","article-title":"Colorimetric detection of unamplified Rift Valley fever virus genetic material using unmodified gold nanoparticles","volume":"184","author":"Zaher","year":"2018","journal-title":"Appl Biochem Biotechnol"},{"key":"2025072915231370000_5.8.e002694.42","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0007700","article-title":"Development and validation of a pen side test for Rift Valley fever","volume":"13","author":"C\u00eatre-Sossah","year":"2019","journal-title":"PLoS Negl Trop Dis"},{"key":"2025072915231370000_5.8.e002694.43","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.3201\/eid2510.181748","article-title":"Genomic characterization of Rift Valley fever virus, South Africa, 2018","volume":"25","author":"van Schalkwyk","year":"2019","journal-title":"Emerg Infect Dis"},{"key":"2025072915231370000_5.8.e002694.44","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0189250","article-title":"Distinct virulence of Rift Valley fever phlebovirus strains from different genetic lineages in a mouse model","volume":"12","author":"Ikegami","year":"2017","journal-title":"PLoS One"},{"key":"2025072915231370000_5.8.e002694.45","doi-asserted-by":"publisher","DOI":"10.1038\/srep27719"},{"key":"2025072915231370000_5.8.e002694.46","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2005.08.034"},{"key":"2025072915231370000_5.8.e002694.47","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.07104-11"},{"key":"2025072915231370000_5.8.e002694.48","doi-asserted-by":"crossref","DOI":"10.3390\/vaccines5030029","article-title":"Current status of Rift Valley fever vaccine development","volume":"5","author":"Faburay","year":"2017","journal-title":"Vaccines"},{"key":"2025072915231370000_5.8.e002694.49","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.coviro.2018.02.001","article-title":"Rift Valley fever vaccines: current and future needs","volume":"29","author":"Dungu","year":"2018","journal-title":"Curr Opin Virol"},{"key":"2025072915231370000_5.8.e002694.50","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1080\/14712598.2019.1662784","article-title":"Candidate vaccines for human Rift Valley fever","volume":"19","author":"Ikegami","year":"2019","journal-title":"Expert Opin Biol Ther"},{"key":"2025072915231370000_5.8.e002694.51","doi-asserted-by":"publisher","DOI":"10.1016\/S2214-109X(18)30346-2"},{"key":"2025072915231370000_5.8.e002694.52","unstructured":"Dimas J . CEPI awards funding agreement worth up to $9.5 million to Colorado State University to develop a human vaccine against Rift Valley fever 2019."},{"key":"2025072915231370000_5.8.e002694.53","unstructured":"WHO . Efficacy trials of Rift Valley fever vaccines and therapeutics guidance on clinical trial design."},{"key":"2025072915231370000_5.8.e002694.54","doi-asserted-by":"publisher","DOI":"10.1089\/vbz.2009.0205"},{"key":"2025072915231370000_5.8.e002694.55","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.39.12.4456-4461.2001"},{"key":"2025072915231370000_5.8.e002694.56","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.02257-15"},{"key":"2025072915231370000_5.8.e002694.57","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.virusres.2012.07.019","article-title":"Detection and identification of Rift Valley fever virus in mosquito vectors by quantitative real-time PCR","volume":"169","author":"Mwaengo","year":"2012","journal-title":"Virus Res"},{"key":"2025072915231370000_5.8.e002694.58","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1128\/CDLI.9.3.713-715.2002","article-title":"Use of reverse transcriptase PCR in early diagnosis of Rift Valley fever","volume":"9","author":"Sall","year":"2002","journal-title":"Clinical and Vaccine Immunology"},{"key":"2025072915231370000_5.8.e002694.59","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.10465"},{"key":"2025072915231370000_5.8.e002694.60","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcv.2007.10.001"},{"key":"2025072915231370000_5.8.e002694.61","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1016\/j.jviromet.2013.07.006","article-title":"Development of a Rift Valley fever real-time RT-PCR assay that can detect all three genome segments","volume":"193","author":"Wilson","year":"2013","journal-title":"J Virol Methods"},{"key":"2025072915231370000_5.8.e002694.62","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.jviromet.2017.06.001","article-title":"A novel highly sensitive, rapid and safe Rift Valley fever virus neutralization test","volume":"248","author":"Wichgers Schreur","year":"2017","journal-title":"J Virol Methods"},{"key":"2025072915231370000_5.8.e002694.63","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.01188-08"}],"container-title":["BMJ Global Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjgh-2020-002694","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,29]],"date-time":"2025-07-29T22:23:24Z","timestamp":1753827804000},"score":1,"resource":{"primary":{"URL":"https:\/\/gh.bmj.com\/lookup\/doi\/10.1136\/bmjgh-2020-002694"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8]]},"references-count":63,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2020,8,17]]},"published-print":{"date-parts":[[2020,8]]}},"alternative-id":["10.1136\/bmjgh-2020-002694"],"URL":"https:\/\/doi.org\/10.1136\/bmjgh-2020-002694","relation":{},"ISSN":["2059-7908"],"issn-type":[{"value":"2059-7908","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,8]]}}}